Dr. Nathan Chen leaves OBI Pharma; Accepts New Role on Company’s Medical Advisory Board

OBI Pharma today announced that Dr. Nathan Chen has resigned his post as Chief Medical Officer for personal reasons, effective from August 10, 2016. Dr. Chen continues to be deeply committed to the success of OBI Pharma and will join the company’s Medical Advisory Board on August 11, 2016.

During his time at OBI Pharma, Dr. Chen led the development of the company’s clinical development strategy and implementation plan for its pipeline portfolio.

“We sincerely appreciate Dr. Chen’s contribution to OBI Pharma during his time as Chief Medical Officer,” said Amy Huang, General Manager, OBI Pharma. “We are delighted that Dr. Chen has chosen to join our Medical Advisory Board as we value his insight and counsel.”

OBI Pharma will announce Dr. Chen’s successor in due course.